Clinical data
Trade names Retavase
AHFS/ Monograph
ATC code B01AD07 (WHO)
CAS Number 133652-38-7 YesY
DrugBank DB00015 YesY
ChemSpider none
KEGG D05721 YesY
Chemical and physical data
Formula C1736H2671N499O522S22
Molar mass 39589.6 g/mol

Reteplase (trade names Retavase, Rapilysin) is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.

Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.

Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.

Reteplase was approved by the Food and Drug Administration in 1996.

As reteplase is able to penetrate inside the thrombi, an enhanced fibrinolytic activity will be achieved → rapid reperfusion → low incidence of bleeding.

This article is issued from Wikipedia - version of the 4/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.